# Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

> **NCT00501293** · PHASE3 · COMPLETED · sponsor: **Noven Therapeutics** · enrollment: 163 (actual)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** Methylphenidate Transdermal System

## Key facts

- **NCT ID:** NCT00501293
- **Lead sponsor:** Noven Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2017-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00501293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00501293, "Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00501293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*